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Humoral Immune Responses of White-Tailed Deer
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BCG Vaccination and Experimental Challenge
with M. bovis䌤
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B. J. Nonnecke,4 T. J. Keefe,5 T. C. Thacker,4 J. C. Rhyan,1 F. E. Aldwell,6 and M. D. Salman2
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Monitoring of the kinetics of production of serum antibodies to multiple mycobacterial antigens can be
useful as a diagnostic tool for the detection of Mycobacterium bovis infection as well as for the characterization
of disease progression and the efficacy of intervention strategies in several species. The humoral immune
responses to multiple M. bovis antigens by white-tailed deer vaccinated with BCG orally via a lipid-formulated
bait (n ⴝ 5), orally in liquid form (n ⴝ 5), and subcutaneously (n ⴝ 6) were evaluated over time after
vaccination and after experimental challenge with virulent M. bovis and were compared to the responses by
unvaccinated deer (n ⴝ 6). Antibody responses were evaluated by using a rapid test (RT), a multiantigen print
immunoassay (MAPIA), a lipoarabinomannan enzyme-linked immunosorbent assay (LAM-ELISA), and immunoblotting to whole-cell sonicate and recombinant antigen MPB83. MAPIA and RT detected minimal to no
antibody responses over those at the baseline to multiple M. bovis antigens in vaccinated white-tailed deer after
challenge. This was in contrast to the presence of more readily detectable antibody responses in nonvaccinated
deer with more advanced disease. The LAM-ELISA results indicated an overall decrease in the level of
production of detectable antibodies against lipoarabinomannan-enriched mycobacterial antigen in vaccinated
animals compared to that in nonvaccinated animals after challenge. Immunoblot data were inconsistent but
did suggest the occurrence of unique antibody responses by certain vaccinated groups to Ag85 and HSP70.
These findings support further research toward the improvement and potential use of antibody-based assays,
such as MAPIA, RT, and LAM-ELISA, as tools for the antemortem assessment of disease progression in
white-tailed deer in both experimental and field vaccine trials.
evaluation of any vaccine candidate is gaining an understanding of the dynamics of a recipient’s immunologic response to vaccination and infection over time in comparison
with the dynamics of the response in unvaccinated subjects
(3, 19, 22). Previous research has shown that monitoring of
the kinetics of production of serum antibodies to multiple
mycobacterial antigens is useful for the characterization of
disease progression and the efficacy of disease treatment
and as a tool for the diagnosis of M. bovis or M. tuberculosis
infection in several species (11, 12, 21, 23, 24, 25).
In the present study, the humoral immune responses to
multiple M. bovis antigens by white-tailed deer vaccinated with
BCG via the oral and the parenteral routes were evaluated by
four different assays over time after vaccination and after experimental challenge with virulent M. bovis. This information
provides an understanding of the differences in the immunologic responses and disease progression in vaccinated and unvaccinated white-tailed deer infected with M. bovis and insight
regarding the appropriate diagnostic tests to be used for the
detection of BTb in a vaccinated population.

Free-ranging white-tailed deer (Odocoileus virginianus) are
wildlife reservoirs for bovine tuberculosis (BTb), caused by
Mycobacterium bovis, in the state of Michigan (15, 18). Current
management strategies, such as population reduction and decreased supplemental feeding, have effectively reduced the
prevalence of disease (15). However, BTb continues to maintain a low-level presence in the wild deer population. The
inclusion of effective field vaccination as part of disease management efforts in deer herds with endemic BTb would significantly aid in efforts to eradicate BTb from this potential wildlife reservoir (14, 16).
Vaccination with M. bovis bacillus Calmette-Guérin (BCG) via
the oral or the parenteral route is effective in protecting
white-tailed deer from disease caused by experimental M.
bovis infection (14, 16). An important component of the
* Corresponding author. Mailing address: USDA/APHIS, National Wildlife Research Center, 4101 LaPorte Ave., Fort Collins,
CO 80521. Phone: (970) 266-6126. Fax: (970) 266-6157. E-mail:
pauline.nol@aphis.usda.gov.
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MATERIALS AND METHODS

Laboratories, Gaithersburg, MD) diluted 1:500 and then received another washing step. Deer antibodies bound to printed antigens were visualized with 5-bromo-4-chloro-3-indolylphosphate–nitroblue tetrazolium (Kirkegaard & Perry
Laboratories). The MAPIA antigen panel was made up of 12 defined proteins.
The following recombinant antigens of M. bovis were purified to near homogeneity as polyhistidine-tagged proteins: ESAT-6 (Rv3875) and CFP10 (Rv3874),
produced at the Statens Serum Institut, Copenhagen, Denmark; MPB59
(Rv1886c), MPB64 (Rv1980c), MPB70 (Rv2875), and MPB83 (Rv2873), produced at the Veterinary Sciences Division, Stormont, Belfast, United Kingdom
(7); and a 16-kDa protein (Acr1, Rv3391) and a 38-kDa protein (PstS1, Rv0934),
purchased from Standard Diagnostics, Seoul, South Korea. Polyprotein fusions
CFP10–ESAT-6 (E6P10) and Acr1-MPB83 (16/83) were constructed as described by Lyashchenko et al. (12). M. bovis culture filtrate (MBCF) was obtained
from a field strain of M. bovis (strain T/91/1378; Veterinary Sciences Division)
cultured in synthetic Sauton’s medium for 21 days. Bovine protein purified
derivative was produced by the Veterinary Laboratories Agency (Weybridge,
Addlestone, United Kingdom).
The results of the MAPIA were evaluated visually to determine the presence
or the absence of bands corresponding to the antigen on the strip. Selected
MAPIA results also underwent semiquantitative densitometry analysis by use of
the scanned strips and Scion Image, a public-domain imaging program from the
U.S. National Institutes of Health (http://rsb.info.nih.gov/nih-image/). The densitometry software produced arbitrary values of the relative absorbance for the
purposes of identifying trends among treatment groups. All densitometry values
were recorded after subtraction of the densitometry readings taken from the
prevaccination strips. The densitometry values obtained at 2 months for MBCF
and 4 months for E6P10 and 16/83 were used for comparisons among the
treatment groups.
Immunoblot assay. The antibody responses of the deer were evaluated over
time by immunoblot analysis with two sets of antigens: a whole-cell sonicate
(WCS) of M. bovis strain 95-1315 and MPB83 (a kind gift from Jim McNair,
AFBI, Belfast, United Kingdom). Mycobacterium bovis WCS was prepared as
described by Waters et al. (23). Electrophoresis and immunoblot assays were
performed by the procedures described by Waters and others (23, 25). Antigen
was electrophoresed through preparative 12% (wt/vol) polyacrylamide gels.
Electrophoretic transfer of the proteins onto pure nitrocellulose was accomplished with a Trans Blot cell (Bio-Rad, Hercules, CA) and sodium phosphate
buffer (25 mM, pH 7.8) at 0.8 A for 90 min. After transfer, the filters were
blocked with PBST and 2% (wt/vol) bovine serum albumin (BSA). After the
filters were blocked, they were placed into the slot blot device and individual
serum samples diluted 1:200 in PBST-BSA were added to independent slots.
After 2 h of incubation at room temperature with gentle rocking, the blots were
washed three times with PBST and incubated with horseradish peroxidaseconjugated anti-goat immunoglobulin G heavy and light chains (Kirkegaard &
Perry Laboratories) diluted 1:20,000 in PBST-BSA for 1.5 h. The blots were
again washed three times with PBST and developed for chemiluminescence in
SuperSignal detection reagent (Pierce Chemical Co.). Comparisons of the reactivities of the serial serum samples to the WCS and MPB83 antigens were
conducted as described by Waters et al. (23). In addition, the Scion Image
program was used to obtain densitometry readings of individual lanes on each
gel’s radiographic image. Lane profile plots were generated for each lane. The
response to the MPB83 antigen was considered positive when a band of the
correct size was visually detected.
LAM-ELISA. Lipoarabinomannan (LAM)-enriched mycobacterial antigen
(PK1315) was prepared from M. bovis strain 95-1315 (PK1315) as described by
Waters et al. (20, 21). Briefly, bacilli harvested from 4-week cultures were
sonicated in PBS, further disrupted with 0.1- to 0.15-mm-diameter glass beads
(Biospec Products, Bartlesville, OK) in a bead beater (Biospec Products), centrifuged, filtered (pore size, 0.22 m), and digested in a 1-mg/ml proteinase K
(Roche Molecular Biochemicals, Indianapolis, IN) solution (50 mM Tris, 1 mM
CaCl2 buffer, pH 8.0) for 1 h at 50°C. The protein concentrations were determined (Bio-Rad), and the antigens were stored at ⫺20°C. Immulon II 96-well
microtiter plates (Dynatech, Chantilly, VA) were used. Each sample was tested
in four wells, with two wells containing no antigen and two wells containing
antigen. For the no-antigen wells, the wells were coated with 100 l/well of 0.05
M carbonate-bicarbonate coating buffer (pH 9.6; C3041; Sigma-Aldrich Corp.,
St. Louis, MO). The antigen-coated wells received 100 l/well of PK1315 diluted
to 20 g/ml in coating buffer. The coated plates were incubated overnight at 4°C.
The plates were washed three times with 200 l/well PBST (Sigma) and were
blocked with 200 l/well commercial milk diluent-blocking solution (diluted 1:20
with distilled H2O [Kirkegaard & Perry Laboratories]). After incubation for 1 h
at 37°C in the blocking solution, the wells were washed nine times with 200
l/well PBST. Test sera were added to the wells (100 l/well). The test and the
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Deer, vaccination, challenge, and necropsy. Serum samples from 22 yearling
white-tailed deer does were utilized for this study. These animals were part of a
larger herd obtained for a vaccine efficacy trial (14). The deer originated from
four BTb-free deer farms throughout the state of Iowa and were housed for the
vaccination and infection studies conducted at the USDA/ARS National Animal
Disease Center (NADC) in Ames, IA. All deer were housed and cared for
according to the guidelines of the Association for Assessment and Accreditation
for Laboratory Animal Care International. The Institutional Animal Care and
Use Committee approved the protocols detailing the procedures and animal care
prior to the initiation of the experiments.
At the beginning of the study, five deer voluntarily consumed 1 ⫻ 109 CFU
BCG Danish strain 1331 orally via a lipid-formulated bait (oral bait group) (1,
14); five deer received 1.9 ⫻ 108 CFU BCG in culture medium orally via a
catheter (oral liquid group), as described by Nol and others (14); six deer
received 3.4 ⫻ 106 CFU BCG subcutaneously in the right shoulder (parenteral
vaccination group); and six deer received culture medium orally via a catheter
and served as unvaccinated controls (nonvaccinated animals). Mycobacterium
bovis BCG Danish strain 1331 in culture and in lipid-formulated pellets was
prepared by Immune Solutions Ltd. at the University of Otago, Dunedin, New
Zealand, as described by Aldwell and others (1). The vaccine doses were determined by standard enumeration techniques by serial dilution plate counting on
Middlebrook 7H11 medium (Becton Dickinson, Cockeysville, MD). Before vaccination and on a monthly basis throughout the study, blood was collected via the
jugular vein for serologic analysis of the antibody responses. Three months after
vaccination, the deer were moved from an outdoor facility to a biosafety level 3
animal building. The animals were separated into rooms with three to four
animals per room, and the vaccinated deer were comingled with the unvaccinated deer. All deer were then challenged with 228 CFU of M. bovis strain 9839
(NADC designation) by the intratonsillar route (114 CFU/tonsil). This strain was
originally isolated from an M. bovis-infected deer in the state of Michigan.
Mycobacterium bovis strain 9839 was grown to mid-log phase on Middlebrook
7H9 medium supplemented with 10% oleic acid-albumin-dextrose complex
(Difco, Detroit, MI) plus 0.05% Tween 80. Bacilli were harvested from the
culture medium by pelleting the cells by centrifugation at 2,000 ⫻ g, washing the
cells twice with 1 ml of phosphate-buffered saline (PBS) solution, and diluting
the cells to the appropriate cell density in 2 ml of PBS. The challenge dose was
determined as described above for the vaccine doses.
Five months after challenge, the deer were euthanized and examined for gross
and microscopic lesions, as well as for mycobacterial colonization, by culture and
PCR analysis (14). For the present study, the following tissues were examined for
the presence of gross lesions consistent with M. bovis infection under a scoring
system described in detail by Palmer and others (16): palatine tonsil, mandibular
lymph node, parotid lymph node, medial retropharyngeal lymph node, tracheobronchial lymph node, mediastinal lymph node, right cranial lung lobe, right
middle and caudal lung lobes, left cranial lung lobe, left caudal lung lobe,
accessory lung lobe, liver, hepatic lymph node, mesenteric lymph node, and
superficial cervical lymph node. The lymph node lesion scores ranged from 0 (no
lesions) to 3 (most severe). The lung lesion scores ranged from 0 (no lesions) to
5 (most severe). Each animal received a total pathology score on the basis of the
sums of the lesion scores assigned to each tissue evaluated. Additional information on gross and microscopic findings, as well as culture and PCR results, can be
found in the report by Nol et al. (14).
RT. A rapid immunochromatographic assay (RT; Cervid TB STAT-PAK,
Chembio Diagnostic Systems, Inc., Medford, NY) was used to detect the antibody responses in the deer. The test employs a unique cocktail of selected M.
bovis antigens and a blue latex bead-based signal detection system. Serum samples were tested as described previously (12). In addition to visual reading,
semiquantitative evaluation of test band intensity was performed with an inhouse-developed computer-assisted optical reader designed to measure the
reflectance at 624 nm. The RT densitometry results obtained at 4 months
postchallenge were utilized to compare the results among the groups.
MAPIA. The multiantigen print immunoassay (MAPIA) was performed as
described by Lyashchenko et al. (11). Briefly, antigens were immobilized on a
nitrocellulose membrane (Schleicher & Schuell, Keene, NH) at a protein concentration of 0.05 mg/ml with a semiautomated airbrush printing device (Linomat IV; Camag Scientific, Inc., Wilmington, DE). The membrane was cut perpendicular to the antigen bands into 4-mm-wide strips. The strips were blocked
for 1 h with 1% nonfat skim milk in PBS with 0.05% Tween 20 (PBST) and were
then incubated for 1 h with serum samples diluted 1:50 in blocking solution.
After the strips were washed, they were incubated overnight with alkaline phosphatase-conjugated anti-deer immunoglobulin G antibody (Kirkegaard & Perry
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RESULTS
Pathology. Five of the 16 vaccinated animals developed lesions consistent with tuberculosis, but none of these animals
received a total pathology score of greater than 3. All six
nonvaccinated animals had lesions in one or more tissues, and
the total pathology scores ranged from 5 to 30 (Table 1). The
number of vaccinated deer with lesions was significantly lower
than the number of nonvaccinated deer with lesions (Fisher’s
exact test, P ⬍ 0.0062). The total lung pathology score, the
total lymph node pathology score, and the lung and lymph
node pathology scores combined were all significantly higher
for the nonvaccinated group than for the vaccinated group
(P ⫽ ⬍0.001, P ⬍ 0.001, and P ⫽ 0.002, respectively, based on
the Wilcoxon rank-sum test) (Fig. 1).
RT. Among the 16 vaccinated deer, only 1 animal developed
detectable antibodies, as determined by RT, at any time during
the study. One of the six deer in the parenteral vaccination
group developed a response, as determined by RT, starting at
3 months postvaccination and remained reactive for 4 months
after challenge. In contrast, five of six deer in the nonvaccinated group developed detectable antibodies, as determined
by RT, by 4 months after M. bovis challenge. Two of those
animals developed a response by 2 months postchallenge, and
four deer did so by 3 months postchallenge. None of the
nonvaccinated deer developed antibodies detectable by RT
before M. bovis challenge. The relative densities obtained from
the RT responses for all deer at 4 months postchallenge are

TABLE 1. Total pathology scores and antibody responses to M. bovis
antigens as measured by MAPIA and RT densitometry in vaccinated
and nonvaccinated deer after M. bovis challengea
Vaccination
group and
animal
identifier

Relative antibody density over that at
the baseline determined by:
RT

Total
pathology
score (avg)

41b,c
0c
5b,c
0c
13c
3/5

0
0
0
0
0
0/5

0
0
0
2
1
3 (0.6)

0
0
0
0
0
0/5

0
0
0
0
0
0/5

0
0
0
0
0
0/5

0
0
0
1
0
1 (0.2)

0
0c
0c
0c
0c
0
0/6

0c
0c
0c
0
16c
0
1/6

0b,c
63b,c
0b,c
83b
0
0
2/6

87b
0
0
0
0
0
1/6

0
0
1
0
3
0
4 (0.7)

94
10c
12
0c
0
0
3/6

16
3c
28
0c
0
45
4/6

96
45c,e
96
0c,e
90
85
5/6

32
20
39
0
27
90
5/6

16
5
11
5
19
30
86 (14)

MAPIA
E6P10

16/83

Oral bait
402
404
406
410
418
Totald

0
0
0c
0c
0c
0/5

0
15b
0c
0c
0c
1/5

Oral liquid
14
20
81
84
416
Total

0
38b
0
0
0
1/5

Parenteral
1
23
26
59
73
91
Total
Nonvaccinated
animals
3
19
22
24
57
422
Total

MBCF

a
Measurements were made 4 months after intratonsillar infection with 228
CFU of M. bovis for E6P10, 16/83, and RT and at 2 months postinfection for
MBCF.
b
The antibody titer was over that at the baseline 1 to 3 months postvaccination, prior to M. bovis challenge.
c
Antibody was detected in the baseline sample.
d
Number of animals with antibodies/total number of animals tested.
e
Antibody was detected in unvaccinated animals 1 to 3 months prior to M.
bovis challenge.

summarized in Table 1. The relative densities of the RT responses in nonvaccinated deer at 4 months postchallenge were
positively correlated (Spearman’s R ⫽ 0.60; P ⫽ 0.003) with
the total combined pathology scores for the same group (Fig.
2). Interestingly, deer 19 and 24, the two animals in the nonvaccinated group with the lowest pathology scores, had the
lowest densitometry readings in that group as well. However,
these two deer still achieved higher pathology scores than any
of the vaccinated deer (Table 1).
MAPIA. The following proteins were recognized by the animals in this study challenge, as determined by MAPIA, and
are reported here in terms of the numbers of deer producing
detectable antibodies to the following antigens after M. bovis
challenge: 16/83 (n ⫽ 19), MBCF (n ⫽ 17), E6P10 (n ⫽ 5),
CFP10 (n ⫽ 4), bovine protein purified derivative (n ⫽ 3), the
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control sera were diluted 1:100 in PBS containing 0.1% gelatin. After incubation
overnight at 4°C with the diluted test sera, the wells were washed nine times with
200 l/well PBST and the plates were incubated for 1 h at 37°C with 100 l/well
horseradish peroxidase-conjugated protein G from a Streptococcus sp. (strain
P8170; Sigma) diluted 1:2,000 in PBS with 0.1% fish gelatin. The wells were
washed nine times with 200 l/well PBST, and the plates were incubated at room
temperature with 100 l/well SureBlue reagent (Kirkegaard & Perry Laboratories). The plates were read kinetically every minute for 15 min at 650 nm by using
an automated enzyme-linked immunosorbent assay (ELISA) plate reader (FlexStation 3; Molecular Devices, Sunnyvale, CA). For each well, the maximum rate
of change for the enzyme (slope of the bell curve) (Vmax) was determined. For
each sample, the raw Vmax value was calculated by subtracting the Vmax value for
the no-antigen well from the Vmax value for the well with antigen. The raw Vmax
values were also calculated for the positive and the negative controls. Finally, the
Vmax for the sample/in relation to a known positive sample (Vmax s/p) was
calculated by the following formula: (Vmax sample ⫺ Vmax negative control)/(Vmax
positive control ⫺ Vmax negative control). Vmax s/p was the normalized number
for the maximum rate of change for the enzyme, and the value was used for data
analysis. The mean Vmax s/p value for the pooled data for the vaccinated animals
was compared to the mean Vmax s/p value for the nonvaccinated animals.
Data analysis. The number of vaccinated animals (pooled) with lesions was
compared to the number of nonvaccinated animals with lesions by Fisher’s exact
test (two by two, one sided; Proc FREQ program of SAS software, version 9.1;
SAS Institute, Cary, NC). Differences determined by the one-sided Fisher’s exact
test to have P values less than or equal to 0.1 were considered significant. The
total pathology scores derived from lymph node lesions, lung lesions, and lymph
node and lung lesions combined for vaccinated and nonvaccinated animals were
also compared by using the Kruskall-Wallis nonparametric one-way analysis of
variance, followed by the Wilcoxon rank-sum test (SAS software, version 9.1;
SAS Institute). Differences were determined to be significant when P values were
less than or equal to 0.1. Correlations between the relative densities obtained
from the RT bands and pathology scores were analyzed by using Spearman’s
rank test (Proc FREQ, SCORR, program of SAS software, version 9.1, SAS
Institute). LAP-ELISA data were analyzed by repeated-measures analysis of
variance (Statview software, version 5.0; SAS Institute). When significant (P ⱕ
0.1) effects were detected, Fisher’s protected least-significant-difference method
was used to compare the data for the different treatment groups on specific
sampling dates. A P value of ⱕ0.1 was considered significant.
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TABLE 2. Numbers of vaccinated and nonvaccinated animals with
detectable antibodies to E6P10, 16/83, and MBCF determined by
MAPIA 1 to 4 months after intratonsillar infection with
228 CFU of M. bovis

Group

Antigen

a

16-kDa protein (n ⫽ 2), MPB83 (n ⫽ 1), and ESAT-6 (n ⫽ 1).
Although these data varied among both individuals and on the
basis of the treatment group, three antigens (16/83, MBCF,
and E6P10) were deemed the most useful for evaluation of the
responses of vaccinated and nonvaccinated deer after M. bovis
challenge. The relative densities measured from the responses
of the deer in the individual treatment groups to 16/83 and
E6P10 at 4 months postinfection and to MBCF at 2 months
postinfection are summarized in Table 1. The overall numbers
of vaccinated animals and nonvaccinated animals producing
detectable antibodies to the three antigens over the 4-month
postinfection period, as determined by MAPIA, are reported
in Table 2.
Relative to the baseline levels (i.e., the preexisting responses, prior to vaccination), four of six deer in the nonvac-

FIG. 2. Positive correlation between relative densities determined
by RT and disease severity in vaccinated and nonvaccinated deer
shown in terms of the pathology scores. Sera were collected at 4
months after challenge with a total of 228 CFU of M. bovis strain 9839.
Statistical analysis was conducted by using Spearman’s rank test (R ⫽
0.60; P ⫽ 0.003).

1

2

3

4

Vaccinated

E6P10
16/83
MBCF

1/16
1/16
5/16

1/16
2/16
5/16

1/16
1/16
5/16

1/16
2/16
5/16

Nonvaccinated

E6P10
16/83
MBCF

0/6
0/6
3/6

2/6b
4/6b
5/6b

2/6c
3/6c
4/6c

3/6b
4/6b
4/6b

a
None of the vaccinated animals responded to more than one antigen
throughout the 4-month postinfection period.
b
Four of six nonvaccinated animals produced detectable antibodies to more
than one antigen at 2 and 4 months postinfection.
c
Two of six nonvaccinated animals produced detectable antibodies to more
than one antigen at 3 months postinfection.

cinated group had produced detectable antibodies to at least
two of the three most useful antigens at 2 and at 4 months
postinfection (Table 2). None of the 16 vaccinated deer produced detectable antibodies to more than one of the antigens
throughout the postinfection period (Table 2). Six of the eight
vaccinated animals that did produce detectable antibodies to
one of the three most useful antigens had also done so before
challenge (data not shown). In the oral bait vaccination group,
zero of five, one of five, and three of five deer had detectable
antibodies to E6P10 and 16/83 (4 months postchallenge) and to
MBCF (2 months postchallenge), respectively (Table 1). One
of five deer in the oral liquid vaccination group had detectable
antibodies to E6P10 postchallenge. However, none of the deer
in the oral liquid group had levels of antibodies to 16/83 or
MBCF over the baseline levels at any time postinfection (Table
1). In the parenteral vaccination group, zero of six, one of six,
and two of six deer responded to E6P10, 16/83, and MBCF,
respectively (Table 1). In contrast, three of six, four of six, and
five of six of the animals in the nonvaccinated group developed
antibodies to E6P10, 16/83, and MBCF, respectively (Tables 1
and 2).
Immunoblots. Specific bands of reactivity to M. bovis WCS
at ⬃10 kDa, ⬃15 kDa, ⬃20 to 25 kDa, ⬃32 kDa, ⬃34 to 35
kDa, ⬃42 kDa, ⬃60 kDa, ⬃68 to 70 kDa, ⬃74 to 76 kDa,
⬃90 kDa, and ⬃125 kDa were detected by immunoblotting
throughout the study. The most reactive proteins were at the
⬃20- to 25-kDa level, as all the deer produced antibodies to
these antigens at some time during the study, including
before vaccination.
Differences in antibody responses to proteins within specific
size ranges were noted among the vaccination groups. During
the first 3 months after M. bovis challenge, four of five animals
in the oral bait vaccination group, two of five in the oral liquid
vaccination group, five of six in the parenteral vaccination
group, and five of six in the nonvaccinated group had responses
to antigen at approximately the 32-kDa level greater than
those detected at the baseline. However, by 4 months postchallenge, five of six nonvaccinated animals continued to produce
antibody responses to these proteins, whereas two of five, two
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FIG. 1. Gross pathology scores for selected lymph node and lung
tissue samples for individual treatment groups. Scoring took place 5
months after intratonsillar infection with 228 CFU of M. bovis. The
lymph node lesion scores ranged from 0 (no lesions) to 3 (most severe).
The lung lesion scores ranged from 0 (no lesions) to 5 (most severe).
Each animal received pathology scores on the basis of the sums of the
lesion scores assigned to each tissue evaluated. ⴱ, the total combined
pathology score for nonvaccinated animals was significantly greater
than the pooled score for vaccinated animals.

No. of animals with detectable
antibodies/total no. of animals at the
following time (mo) postinfection:
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FIG. 3. LAM-ELISA results as mean Vmax s/p values for nonvaccinated animals versus the mean value for vaccinated animals. The mean
Vmax s/p values were calculated for nonvaccinated animals and vaccinated animals at each time point relative to the times of vaccination
and challenge. Standard errors are reported for each mean. The Vmax
s/p was the normalized number for the maximum rate of change for the
enzyme. PV, postvaccination; PC, postchallenge; ⴱ, the mean Vmax s/p
value for vaccinated animals was significantly lower than the mean
Vmax s/p value for nonvaccinated animals.

DISCUSSION
Our MAPIA, RT, and LAM-ELISA results indicate that
vaccinated white-tailed deer, which developed fewer and less
severe lesions than nonvaccinated animals after M. bovis infection, as described here and by Nol et al. (14), generally harbor
lower and/or diminishing levels of detectable circulating antibodies to M. bovis antigens than nonvaccinated deer with more
advanced disease. This finding is consistent with those of previous studies, in which associations between the severity of
disease caused by M. bovis infection and the levels of antibody
production were noted (5, 10, 12, 23, 26).
Using RT and/or MAPIA, we were generally able to distinguish vaccinated and M. bovis-challenged deer with minimal
lesion pathology from nonvaccinated and challenged deer with
more advanced lesion development. In the present study, with
one exception, none of the vaccinated deer responded by RT
or produced detectable antibodies to more than one of the
three most useful antigens by MAPIA. One of the two nonvaccinated animals that did not develop a detectable antibody
response after infection to at least two of the three antigens
analyzed by MAPIA did react by RT postinfection. The single
nonvaccinated animal that tested negative by both assays was
one of the two animals with the lowest lesion scores. It is
possible that, given time, this animal would have reacted by
these tests as the disease increased in severity; it is also possible
that this animal had some resistance to M. bovis infection and
may not have experienced a rapid development of pathology.
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of five, and three of six deer in the oral bait, oral liquid, and
parenteral vaccination groups, respectively, maintained antibody responses (data not shown). Of the two deer in the oral
bait vaccination group that maintained antibodies to the 32kDa protein, one deer produced a very weak response. One of
the two deer in the oral liquid vaccination group had a weak
response, whereas the other deer (deer 84) had a very strong
response and was the only deer in that group to have lesions.
Unlike in the other vaccination groups, all three deer in the
parenteral vaccination group produced strong antibody responses to the 32-kDa protein. Two of the three deer did not
sustain lesions by the end of the study, and the third deer had
a very low pathology score. The deer in the nonvaccinated
group (deer 24) that did not respond to the 32-kDa protein was
one of two deer that had the lowest pathology scores (score, 5).
The other nonvaccinated deer with a low pathology score (deer
19) had only a weak response to the 32-kDa protein relative to
the responses of the other four animals that responded.
All of the deer in the oral bait and the parenteral vaccination
groups showed antibody responses to proteins at the 68- to
70-kDa level at some time in the 4 months postchallenge. At 4
months postchallenge, four of five of the deer in the oral bait
vaccination group and four of six deer in the parenteral vaccination group still showed the production of antibodies to these
proteins. Only one animal in each of the other two groups
developed a response to these antigens. All of the deer in the
parenteral vaccination group deer and two of the deer in the
oral bait vaccination group had already developed antibodies
to these proteins after vaccination.
Regarding the MPB83-specific immunoblot assay, there
were no patterns in antibody response to this antigen among
the vaccine groups. Three of five deer in the oral bait vaccination group became positive for this antigen at different time
points after vaccination, of which only one developed an
increased response at 1 month postchallenge, which persisted to 4 months postchallenge. None of the deer in the
oral liquid vaccination group developed antibodies to
MPB83 detectable by immunoblotting after vaccination or
challenge; however, the prevaccination serum of one of the
animals did have a response, but the animals was negative by
every test thereafter. One of five deer in the parenteral
vaccination group became weakly positive for MPB83 at 1
month postvaccination, and this response disappeared by 2
weeks after challenge. One of six deer in the nonvaccinated
group developed detectable antibodies to MPB83 by immunoblotting 2 weeks after challenge and maintained this response until 4 months postchallenge.
LAM-ELISA. Mean Vmax s/p values obtained from pooled
data for vaccinated animals and nonvaccinated animals indicated a trend of increasing detectable antibodies to LAMenriched mycobacterial antigens in the nonvaccinated group
after M. bovis challenge, whereas the vaccinated animals had
an initial increase followed by a consistent decrease in detectable antibodies. The mean Vmax s/p values were not
significantly different between the two groups until the final
sampling point, which was at 16 weeks after infection (P ⫽
0.002, based on Fisher’s protected least-significant-difference method) (Fig. 3).
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orally vaccinated groups, it is possible that mucosal exposure to
this antigen prior to challenge leads to a reduction in the
antibody response over time after challenge and may correspond to a lack of lesion development. Alternatively, effective
mucosal vaccination may limit the antigen load detected by the
host in the form of antibody production. That the animals in
the parenteral vaccination group did not respond in this manner could be a result of the more effective sensitization to the
Ag85 complex afforded by vaccination by the parenteral route
compared to that afforded by vaccination by the oral routes.
The protein(s) in the 68- to 70-kDa range probably corresponds to a heat shock protein (HSP70) that has been shown to
be immunogenic (8, 9). It is unclear why the animals in the
parenteral and oral bait vaccination groups responded more
consistently to this antigen than the animals in the other
groups. More research needs to be conducted in order to
understand the significance of the responses to both sets of
proteins by BCG-vaccinated white-tailed deer.
The animals in this study did not produce readily detectable
antibody responses to MPB83 by immunoblotting or MAPIA.
This is in contrast to the observations from previous studies
with cervids in which MPB83 was found to be immunodominant in these tests (6, 13, 23). However, when this antigen was
combined with the 16-kDa protein (also known as Acr1), it was
the most readily detected antigen by MAPIA in this study and
was one of the most readily detected antigens in other studies
as well (6, 13, 23, 24). These results highlight the variability of
the responses by deer, as well as the variability of the responses
by many other host species, to mycobacterial antigens on both
an individual and a herd basis. These types of findings are not
limited to M. bovis infections and are observed in the face of a
variety of mycobacterial infections. This could be due to genetic differences among individuals and herds, as well as environmental factors. The results of this study and others highlight the importance of the use of a multiantigen approach, and
a continued search for effective antigens is needed to develop
more sensitive and specific serologic assays for the evaluation
of vaccines and disease progression, as well as the general
diagnosis of M. bovis infection in all species. (6, 13, 21, 23).
In conclusion, white-tailed deer that were protected from
severe disease due to vaccination with BCG, either orally or
parenterally, produced either no detectable antibody responses
or decreasing antibody levels, as determined by MAPIA, RT,
and LAM-ELISA, compared to the antibody responses and the
antibody levels of nonvaccinated deer inoculated with M. bovis.
These results support the potential of antibody-based assays as
useful indicators of vaccine efficacy in experimental vaccine
trials as well as for the monitoring of disease in vaccinated
free-ranging deer populations. In addition, although the immunoblotting data provided limited insight regarding vaccineinduced protection against disease, they do encourage the further investigation of the immune responses to the Ag85
complex and HSP70 in deer vaccinated with BCG or similarly
attenuated M. bovis constructs. More research on the development of serologic assays for the detection of immune responses
to vaccination and M. bovis infection is needed. In addition,
more expansive, longer-term studies on the safety and efficacy
of BCG against M. bovis infection in white-tailed deer are
imperative, so that vaccination may ultimately be used for the
management of wild deer populations affected by BTb.
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These tests could serve as antemortem tools to aid researchers
with the evaluation of the efficacy of a vaccine against M. bovis
infection in deer. With this scenario, detection of the production of high levels of antibodies to M. bovis antigens would be
indicative of vaccine failure.
Antibody-based tests could be used to evaluate the status of
BTb in a free-ranging, vaccinated herd through the testing of
live animals. The tests could identify severely affected animals
that should be removed from the population to prevent
shedding of the organism and the further spread of infection. Vaccine-protected animals with no or minimal lesion
development would remain in the herd, as it has been suggested that such vaccinated deer experience minimal pathological changes postinfection and, even though they are infected, are not considered an important source of M. bovis
to the environment for transmission to other animals (4).
The present study was limited to the evaluation of the humoral immune responses of small numbers of vaccinated and
unvaccinated white-tailed deer in the first 4 to 5 months after
challenge with M. bovis. Studies involving large wildlife species
at a high biosafety level often suffer from a low power and a
short duration due to the great expense, logistical issues, and
animal welfare considerations. Although obstacles exist, it
would be extremely useful to conduct follow-up experiments
with larger sample sizes and of a longer duration that monitor
the postchallenge antibody responses in both vaccinated and
unvaccinated deer. BCG-vaccinated white-tailed deer may acquire long-term protection (⬎1 year) from the development of
severe disease, as has been shown in red deer (4). Whether
white-tailed deer continue producing similar results by
MAPIA, RT, and LAM-ELISA after a year or longer following
vaccination and M. bovis challenge would be of great interest
and utility to a field vaccination program.
The results of immunoblotting with the WCS antigen suggest that the captive deer used in this study had prior exposure
to environmental mycobacteria, although we did not isolate
these organisms from the deer’s tissues. Ongoing studies evaluating the responses of captive and free-ranging deer to various WCS antigens (i.e., from M. kansasii, M. avium, M. avium
subsp. paratuberculosis, and M. bovis) indicate that deer are
constantly exposed to antigens, presumably ubiquitous mycobacteria present in their environment, that elicit antibody reactive to mycobacterial WCS (6; W. R. Waters, personal observation). Obviously, preexisting responses complicate the
analysis of specific responses to vaccination and infection and
likely affect vaccine efficacy and disease progression in both
experimental and field situations (2, 22).
Proteins at the 32-kDa and the 68- to 70-kDa levels elicited
relatively unique antibody response patterns among the treatment groups, as detected by immunoblotting. The 32-kDa protein most likely corresponds to the immunodominant antigen
85 (Ag85) complex. The Ag85 complex is a member of the
mycolyltransferase family found in all mycobacteria and represents a major fraction of the proteins secreted in culture
filtrates of M. bovis, including BCG (17, 27). The Ag85 complex has effectively been used in the form of a DNA vaccine to
boost the protective effects of BCG vaccination in mice and
cattle. Although it is unclear why the nonvaccinated animals
had prolonged responses to the Ag85 complex relative to the
lengths of the responses of the other groups, particularly the
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